My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 385

    1.

    An economic analysis of captopril in the treatment of diabetic nephropathy. The Collaborative Study Group.

    Rodby RA, Firth LM, Lewis EJ.

    Diabetes Care. 1996 Oct;19(10):1051-61.PMID: 8886549 [PubMed - indexed for MEDLINE]Related articles

    2.

    Economic evaluation of ACE inhibitor treatment of nephropathy in patients with insulin-dependent diabetes mellitus in Italy.

    Garattini L, Brunetti M, Salvioni F, Barosi M.

    Pharmacoeconomics. 1997 Jul;12(1):67-75.PMID: 10169388 [PubMed - indexed for MEDLINE]Related articles

    3.

    The cost-effectiveness of losartan in type 2 diabetics with nephropathy in Switzerland--an analysis of the RENAAL study.

    Szucs TD, Sandoz MS, Keusch GW.

    Swiss Med Wkly. 2004 Aug 7;134(31-32):440-7.PMID: 15389347 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Cost effectiveness of ACE inhibitor treatment for patients with type 1 diabetes mellitus.

    Dong FB, Sorensen SW, Manninen DL, Thompson TJ, Narayan V, Orians CE, Gregg EW, Eastman RC, Dasbach EJ, Herman WH, Newman JM, Narva AS, Ballard DJ, Engelgau MM.

    Pharmacoeconomics. 2004;22(15):1015-27.PMID: 15449965 [PubMed - indexed for MEDLINE]Related articles

    5.

    Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European Union.

    Gerth WC, Remuzzi G, Viberti G, Hannedouche T, Martinez-Castelao A, Shahinfar S, Carides GW, Brenner B.

    Kidney Int Suppl. 2002 Dec;(82):S68-72.PMID: 12410859 [PubMed - indexed for MEDLINE]Related articles

    6.

    Losartan reduces the costs of diabetic end-stage renal disease: an Asian perspective.

    Seng WK, Hwang SJ, Han DC, Teong CC, Chan J, Burke TA, Carides GW, Choi YJ.

    Nephrology (Carlton). 2005 Oct;10(5):520-4.PMID: 16221106 [PubMed - indexed for MEDLINE]Related articles

    7.

    Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation.

    Herman WH, Shahinfar S, Carides GW, Dasbach EJ, Gerth WC, Alexander CM, Cook JR, Keane WF, Brenner BM.

    Diabetes Care. 2003 Mar;26(3):683-7.PMID: 12610022 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Modelling and costing the consequences of using an ACE inhibitor to slow the progression of renal failure in type I diabetic patients.

    Hendry BM, Viberti GC, Hummel S, Bagust A, Piercy J.

    QJM. 1997 Apr;90(4):277-82.PMID: 9307762 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective.

    Burgess ED, Carides GW, Gerth WC, Marentette MA, Chabot I; Canadian Hypertension Society.

    Can J Cardiol. 2004 May 1;20(6):613-8.PMID: 15152291 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Cost-effectiveness of losartan in diabetic nephropathy: a Greek perspective.

    Stafylas PC, Sarafidis PA, Lasaridis AN, Tsakni E, Niakas DA, Dombros NV, Grekas DM, Bakris GL.

    J Nephrol. 2007 Nov-Dec;20(6):703-15.PMID: 18046673 [PubMed - indexed for MEDLINE]Related articles

    11.

    An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings.

    Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, Cordonnier DJ.

    Nephrol Dial Transplant. 2003 Oct;18(10):2059-66.PMID: 13679481 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    [Clinical and health economic implications of early treatment with irbesartan of patients with type 2 diabetes mellitus, hypertension and nephropathy]

    Palmer AJ, Roze S, Rodby RA, Valentine WJ, Ritz E, Lehnert H.

    Dtsch Med Wochenschr. 2006 Aug 4;131(31-32):1721-6. German. PMID: 16868875 [PubMed - indexed for MEDLINE]Related articles

    13.

    The impact of losartan on the lifetime incidence of ESRD and costs in Mexico.

    Arredondo A, Burke TA, Carides GW, Lemus E, Querol J.

    Rev Invest Clin. 2005 May-Jun;57(3):399-405.PMID: 16187699 [PubMed - indexed for MEDLINE]Related articles

    14.

    The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy.

    Carides GW, Shahinfar S, Dasbach EJ, Keane WF, Gerth WC, Alexander CM, Herman WH, Brenner BM; RENAAL Investigators.

    Pharmacoeconomics. 2006;24(6):549-58.PMID: 16761903 [PubMed - indexed for MEDLINE]Related articles

    15.

    Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes.

    Rosen AB, Hamel MB, Weinstein MC, Cutler DM, Fendrick AM, Vijan S.

    Ann Intern Med. 2005 Jul 19;143(2):89-99.PMID: 16027450 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors.

    Golan L, Birkmeyer JD, Welch HG.

    Ann Intern Med. 1999 Nov 2;131(9):660-7.PMID: 10577328 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group.

    Laffel LM, McGill JB, Gans DJ.

    Am J Med. 1995 Nov;99(5):497-504.PMID: 7485207 [PubMed - indexed for MEDLINE]Related articles

    18.

    Is antihypertensive treatment the same for NIDDM and IDDM patients?

    Parving HH.

    Diabetes Res Clin Pract. 1998 Apr;39 Suppl:S43-7. Review.PMID: 9649959 [PubMed - indexed for MEDLINE]Related articles

    19.

    Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance.

    Schädlich PK, Brecht JG, Brunetti M, Pagano E, Rangoonwala B, Huppertz E.

    Pharmacoeconomics. 2001;19(5 Pt 1):497-512.PMID: 11465309 [PubMed - indexed for MEDLINE]Related articles

    20.

    An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting.

    Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, Bilous RW.

    J Hum Hypertens. 2004 Oct;18(10):733-8.PMID: 15116142 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity